Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
Savino
S
Sciascia
aResearch Fellow in Thrombosis and Haemostasis, Guy's and St Thomas' Guy's & St Thomas' Hospital, London, UK bCentro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Italy cConsultant in Thrombosis & Thrombophilia dProfessor of Thrombosis & Haemostasis, Kings Health Partners & Consultant in Thrombosis & Thrombophilia, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Sciascia
S
Savino
Karen
K
Breen
Beverley J
BJ
Hunt
D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069552:Rivaroxaban / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors; D055815:Young Adult
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014812:Vitamin K; D000069552:Rivaroxaban